Belatacept denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belatacept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step-Therapy Requirements to Belatacept

Step-therapy (also called fail-first) policies require that a patient try one or more less expensive or lower-tier drugs before the plan will authorize coverage of a specialty agent. For belatacept, UnitedHealthcare's step-therapy protocol typically designates standard calcineurin-inhibitor–based regimens as required first-step agents. A step-therapy denial means the plan's system does not have documentation confirming those prior steps were completed, or that they failed or were clinically inappropriate.

## Why This Denial Is Appealable

Federal step-therapy rules and a growing number of state override laws prohibit plans from requiring step therapy when a patient has already tried and failed the required agents, or when those agents are contraindicated or otherwise clinically inappropriate. If your transplant history includes prior immunosuppression — which is almost always the case — the documentation to override the step requirement likely already exists in your chart.

## Federal Appeal Framework

• ACA §2719 external review: Available after exhausting internal appeals, generally within approximately four months of denial (confirm the exact deadline on your EOB). IROs frequently overturn step-therapy denials when prior treatment history is well documented.
• ERISA §503: Entitles employer-plan members to the specific step-therapy criteria applied and the full-and-fair review process.
• Step-therapy override statutes: Many states have enacted laws requiring plans to grant step-therapy exceptions when the required first-step drug was previously tried and failed, was contraindicated, or would cause harm. Ask your state insurance department whether an override statute applies to your plan.
• Expedited review: Available for urgent situations; relevant for transplant patients at rejection risk.

## Concrete Appeal Steps

1. Obtain the UHC step-therapy criteria for belatacept — specifically, the list of required prior agents. 2. For each required prior agent, identify the corresponding chart documentation of use, outcome, discontinuation reason, or clinical contraindication. 3. Have the transplant physician draft an override request letter that walks through each required step with chart-based evidence. 4. Submit this as both a step-therapy override request and a formal internal appeal. 5. If denied, escalate to external IRO review and, if applicable, a state insurance department complaint.

## Documentation to Gather

• Complete immunosuppression history: every agent tried post-transplant with start dates, stop dates, doses (from the chart, not asserted here), and the documented outcome or reason for discontinuation.
• Toxicity or rejection records: lab results, biopsy reports, or clinical notes documenting why a required step-therapy agent failed or could not be used.
• Prescriber step-therapy override letter: addresses each required step individually using chart evidence and references the FDA-approved belatacept prescribing label and the applicable transplant society guideline for clinical context.

## Criteria-Mapping Structure

List every required prior drug from UHC's step-therapy policy. For each, create a row with the policy requirement, the corresponding chart documentation, and the outcome or contraindication note. This exhaustive table is the most persuasive format for an IRO reviewing a step-therapy dispute.